A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Aardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC
Aardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC
BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival
BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival
BioNTech, UPenn team up for $50M seed fund
BioNTech, UPenn team up for $50M seed fund
Genmab terminates Phase 3 lung cancer asset that BioNTech ditched
Gen­mab ends de­vel­op­ment of Phase 3 lung can­cer as­set that BioN­Tech ditched ear­li­er Gen­mab is end­ing clin­i&sh...
#SABCS25: BioNTech, BMS unwrap Phase 2 data for PD-L1xVEGF-A bispecific in breast cancer
#SABCS25: BioNTech, BMS unwrap Phase 2 data for PD-L1xVEGF-A bispecific in breast cancer
ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing - Pharmaceutical Technology
ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing Pharmaceutical Technology
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page